{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:39:32Z","timestamp":1788503972775,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mcna.2020.09.010","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T10:17:35Z","timestamp":1610619455000},"page":"247-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Managing Cardiovascular Risk in Patients with Rheumatic Disease"],"prefix":"10.1016","volume":"105","author":[{"given":"Lyn D.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2020.09.010_bib2","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib6","doi-asserted-by":"crossref","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"10","author":"Baghdadi","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.010_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","volume":"41","author":"van Sijl","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.010_bib12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10046","key":"10.1016\/j.mcna.2020.09.010_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.010_bib15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/acr.21627","article-title":"Effect of body mass index on mortality and clinical status in rheumatoid arthritis","volume":"64","author":"Wolfe","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"14","key":"10.1016\/j.mcna.2020.09.010_bib16","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/archinte.165.14.1624","article-title":"Paradoxical effect of body mass index on survival in rheumatoid arthritis","volume":"165","author":"Escalante","year":"2005","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrrheum.2015.93","article-title":"Debunking the obesity\u2013mortality paradox in RA","volume":"11","author":"Sattar","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.010_bib18","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39136","article-title":"Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis","volume":"67","author":"Baker","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.010_bib19","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3899\/jrheum.130365","article-title":"Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: A 10-year observational cohort study","volume":"40","author":"Ajeganova","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","article-title":"The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.010_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib23","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: A five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.010_bib24","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","article-title":"Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis","volume":"121","author":"Libby","year":"2008","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"21","key":"10.1016\/j.mcna.2020.09.010_bib26","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1161\/CIRCULATIONAHA.112.120410","article-title":"Anti-tumor necrosis factor- therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis","volume":"126","author":"Maki-Petaja","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.md.0000101572.76273.60","article-title":"Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease","volume":"82","author":"Gonzalez-Juanatey","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.010_bib28","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","article-title":"Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease","volume":"73","author":"Karpouzas","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.mcna.2020.09.010_bib29","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/eurheartj\/ehn356","article-title":"Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis","volume":"29","author":"Pundziute","year":"2008","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.mcna.2020.09.010_bib31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/archinte.1997.00440340060005","article-title":"Gout and risk for subsequent coronary heart disease","volume":"157","author":"Gelber","year":"1997","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/fampra\/cmg413","article-title":"Gout, Just a nasty event or a cardiovascular signal? a study from primary care - PubMed","volume":"20","author":"Janssens","year":"2003","journal-title":"Fam Pract"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","article-title":"Gout and coronary heart disease: The framingham study","volume":"41","author":"Abbott","year":"1988","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib34","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","article-title":"Increased risk of vascular disease associated with gout: A retrospective, matched cohort study in the UK Clinical Practice Research Datalink","volume":"74","author":"Clarson","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/art.27338","article-title":"Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort","volume":"62","author":"Bhole","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib37","doi-asserted-by":"crossref","first-page":"e32668","DOI":"10.1371\/journal.pone.0032668","article-title":"Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 Study","volume":"7","author":"St\u00f6ckl","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib38","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2003-030242","article-title":"The emergence of the metabolic syndrome with menopause","volume":"88","author":"Carr","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and Coronary Heart Disease: A Systematic Review and Meta-Analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib40","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases five-year Japanese Cohort Study","volume":"69","author":"Kuwabara","year":"2017","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2020.09.010_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","article-title":"Hyperuricemia and endothelial function: From molecular background to clinical perspectives","volume":"278","author":"Maruhashi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mcna.2020.09.010_bib43","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/rheumatology\/keq184","article-title":"Association between endothelial dysfunction and hyperuricaemia | Rheumatology | Oxford Academic","volume":"49","author":"Ho","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.116.08436","article-title":"Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women","volume":"69","author":"Prasad","year":"2017","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/erc.11.29","article-title":"Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach","volume":"9","author":"Higgins","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"7081","key":"10.1016\/j.mcna.2020.09.010_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.010_bib47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib48","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"23","key":"10.1016\/j.mcna.2020.09.010_bib49","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/heartjnl-2017-311214","article-title":"Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders","volume":"103","author":"Dregan","year":"2017","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D","article-title":"Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus","volume":"42","author":"Manzi","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"25","key":"10.1016\/j.mcna.2020.09.010_bib51","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/03009742.2013.803150","article-title":"Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients","volume":"43","author":"Valero-Gonzalez","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib53","doi-asserted-by":"crossref","first-page":"e0174572","DOI":"10.1371\/journal.pone.0174572","article-title":"Excess atherosclerosis in systemic lupus erythematosus, - A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls","volume":"12","author":"Gustafsson","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib54","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2009.115535","article-title":"A\u00a0STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus","volume":"69","author":"Svenungsson","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2020.09.010_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: A comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J\u00a0Autoimmun"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.20780","article-title":"Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations","volume":"52","author":"Frosteg\u00e5rd","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5 SPEC. ISS","key":"10.1016\/j.mcna.2020.09.010_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0961203308089988","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"17","author":"Frosteg\u00e5rd","year":"2008","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib58","doi-asserted-by":"crossref","first-page":"e37000","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib59","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/BOR.0000000000000307","article-title":"Update on cardiovascular disease in lupus","volume":"28","author":"Lewandowski","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"20","key":"10.1016\/j.mcna.2020.09.010_bib60","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.108.771170","article-title":"Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury","volume":"120","author":"Mayadas","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib61","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.010_bib64","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2012-202075","article-title":"Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis","volume":"72","author":"Stavropoulos-Kalinoglou","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/annrheumdis-2013-203291","article-title":"Individualised exercise improves endothelial function in patients with rheumatoid arthritis","volume":"73","author":"Metsios","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10022","key":"10.1016\/j.mcna.2020.09.010_bib66","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"9493","key":"10.1016\/j.mcna.2020.09.010_bib67","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib68","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A\u00a0multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","article-title":"Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study","volume":"85","author":"Fosb\u00f8l","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"9894","key":"10.1016\/j.mcna.2020.09.010_bib70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib71","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study","volume":"73","author":"Lindhardsen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.010_bib72","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2020.09.010_bib73","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib74","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib75","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/acr.23611","article-title":"Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis","volume":"71","author":"Wilson","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib76","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kem169","article-title":"Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13063-017-2396-3","article-title":"Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial","volume":"19","author":"Hartman","year":"2018","journal-title":"Trials"},{"issue":"9313","key":"10.1016\/j.mcna.2020.09.010_bib78","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib79","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.010_bib80","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.010_bib81","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","article-title":"Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis","volume":"76","author":"Ozen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.010_bib82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","article-title":"Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis","volume":"298","author":"Wasko","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib83","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.010_bib84","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.010_bib85","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: Anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib86","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.010_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"10.1016\/j.mcna.2020.09.010_bib88","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.mcna.2020.09.010_bib89","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMe1914378","article-title":"Inflammation as a treatment target after acute myocardial infarction","volume":"381","author":"Newby","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.010_bib90","doi-asserted-by":"crossref","first-page":"653.e7-16","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: A cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.010_bib91","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.amjmed.2015.11.003","article-title":"Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study","volume":"129","author":"Larsen","year":"2016","journal-title":"Am J Med"},{"issue":"13","key":"10.1016\/j.mcna.2020.09.010_bib92","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252030122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252030122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:45:27Z","timestamp":1758419127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002571252030122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S002571252030122X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Cardiovascular Risk in Patients with Rheumatic Disease","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}